All In Biotech

Drug Trial Radar · NCT06732895

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-18 Years of Age) With Achondroplasia.

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

25

Actual

Start

Dec 10, 2024

Primary completion

Sep 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Ascendis Pharma A/SIndustry
Sponsor type
Industry
First posted
Dec 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.

Conditions

  • Achondroplasia

Interventions

  • NavepegritideDrug

    Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks

  • Placebo for navepegritideDrug

    Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Growth VelocityTime frame: 52 weeks

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • Ascendis Investigational Site

    Montreal, Canada

  • Ascendis Investigational Site

    Copenhagen, Denmark

  • Ascendis Investigational Site

    Paris, France

  • Ascendis Investigational Site

    Dublin, Ireland

  • Ascendis Investigational Site

    Norwich, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.